Product Portfolio

Our Product Portfolio in Vietnam

In Vietnam, STADA Pymepharco proudly owns one of the largest pharmaceutical portfolios among both international and local companies – with nearly 400 products, including around 250 Generic (Rx) medicines and close to 150 Consumer Healthcare (CHC) products.

By combining the global expertise of STADA Group with deep market insights and a strong local legacy, STADA Pymepharco continuously expands its portfolio to deliver German-standard healthcare solutions – meeting the growing and diverse needs of domestic consumers while supporting a long-term strategy for sustainable export growth.

Tra cứu hoạt chất

Generics (Rx)

STADA Pymepharco has a strong competitive edge in the Generics segment, with a portfolio of nearly 250 products covering a broad range of key therapeutic areas in modern medicine: antibiotics, anti-inflammatory, gastrointestinal, cardiovascular, metabolic, diabetes treatments, and many more.

All products are developed based on extensive research and strictly comply with the stringent EU-GMP and WHO-GMP standards, ensuring bioequivalence, treatment efficacy, and patient safety in every product. Our Generics portfolio are trusted by healthcare professionals across Vietnam and play a vital role in improving treatment accessibility and reducing the cost burden for patients.

Consumer Healthcare (CHC)

STADA Pymepharco proudly represents the global expertise and quality commitment of STADA Group – one of the world’s fastest-growing pharmaceutical companies in Consumer Healthcare (CHC) segment. In Vietnam, we offer nearly 150 CHC products that support prevention, symptom relief, and healthy living.

Renowned international brands such as Tatanol®, Kamistad®, Liverton®, Cetebe®, ArthroStop®, GinkoPrim®, Nizoral®, Zoflora®, Grippostad®, SNUP®, Silomat® and Hirudoid® are also being gradually introduced to Vietnamese consumers – contributing to raising healthcare standard nationwide.